| Name | Title | Contact Details |
|---|
Agel Enterprises is a Lehi, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Children’s of Alabama has provided specialized medical care for ill and injured children across the state and throughout the southeastern U.S. since 1911. For the past three years, Children’s has been ranked among the best children’s hospital programs in the nation by US News & World Report. Last year, patients made more than 634,000 outpatient and nearly 14,000 inpatient visits to Children’s from every county in Alabama and from 47 other states. With more than 2 million square feet, it is the third largest pediatric medical facility in the U.S. Children’s offers inpatient and outpatient services across its Russell Campus on Birmingham’s historic Southside with additional outpatient services provided at Children’s South and Children’s on 3rd. Primary care is provided at more than a dozen offices in communities across central and north Alabama. The Benjamin Russell Hospital for Children is the only hospital in Alabama dedicated solely to the care and treatment of children. It is a private, not-for-profit hospital that serves as the primary site of the University of Alabama at Birmingham (UAB) pediatric medicine, surgery, research and residency programs.
HealthPresence is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accent Biomedical is a Stow, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.